Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly.

Trial Profile

A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atesidorsen (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 04 Apr 2017 Status changed from recruiting to completed.
    • 11 Mar 2016 According to Antisense media release, full dosing is expected to be completed in June 2016.
    • 09 Sep 2015 According to Antisense Therapeutics, dosing of patients will be completed by end of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top